Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
Go back to Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer| VERASTEM SHS (NASDAQ: VSTM) | Delayed: 7.44 -0.11 (1.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.55 | 52 Week High | $2.43 | |||
| Open | $7.58 | 52 Week Low | $1.05 | |||
| Day High | $7.84 | P/E | N/A | |||
| Day Low | $7.40 | EPS | $-1.79 | |||
| Volume | 4,496,847 | |||||
